Bone and Mineral Metabolism Disorders News

The FDA granted 510(k) clearance to Boston Scientific Corporation for its LithoVue Elite Single-Use Digital Flexible Ureteroscope System, according to a press release.

Compared with patients in European countries and Japan, patients using in-center hemodialysis in the United States showed a significant increase in serum phosphorous levels , according to data published in Kidney Medicine.

Ardelyx Inc. has been granted an appeal to a complete response letter issued last year by the FDA regarding the company’s new drug application for its phosphate absorption inhibitor drug Xphozah.

Shivam Joshi, MD, knows he has few options for his patients on dialysis when it comes to the management of hyperphosphatemia. And none are very effective.

The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis drug Prolia, according to a drug safety communication.

ORLANDO — Using a real-time potassium monitoring device in patients on hemodialysis saves more money than the usual care and increases quality of life, according to a presenter at ASN Kidney Week.

An FDA advisory committee voted 9-4 in favor of the use of Xphozah as a monotherapy for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis.

Due to a significant association between the urine to phosphate-to-creatinine ratio and mortality among individuals without chronic kidney disease, researchers suggest this may be a predictor for future adverse events in this population.

Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine, according to a company press release.

Compared with healthy controls, patients with chronic kidney disease or on hemodialysis have lower serum zinc levels more frequently than reported in daily clinical practice, according to data published in the Journal of Renal Nutrition.